Cabozantinib s-malate is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Cabozantinib S-malate was developed by Exelixis.
The API has now reached off-patent status, after being launched in 2012.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Cabozantinib S-malate and many others, contact info@pharmacheminvestor.com